News in brief: PPIs may impair efficacy of immunotherapy; Hep B app in Indigenous languages; Specialty training colleges have ‘dirty secret’

PPIs may impair efficacy of checkpoint inhibitors Proton pump inhibitors (PPIs) may reduce the effectiveness of some immune checkpoint inhibitor (ICI) cancer treatments by causing gut dysbiosis, Australian researchers say. A retrospective review of outcomes for 1202 lung cancer participants in the IMPower150 trial of immunotherapies found that PPI use was independently associated with worse ...

Already a member?

Login to keep reading.

© 2022 the limbic